Retro Biosciences wants to sell you a decade.

Right now, somewhere in Adelaide, a healthy volunteer is swallowing the most ambitious pill in biotech.

The pill is called RTR242. It is small, unglamorous, and designed to do something deceptively mundane: help aging cells take out their own garbage. In a clinical unit half a world away from Retro Biosciences' Redwood City labs, a randomized, double-blind, placebo-controlled trial is quietly testing whether a drug can restore one of the body's oldest housekeeping systems. The CEO's summary of how it is going: "super good." No dose-limiting toxicities. Data expected in August 2026.

This is what a longevity company looks like once it stops talking about living forever and starts filling out trial paperwork. Retro Biosciences spent its first years in relative quiet. In 2025 it crossed the line that separates ideas from medicine - it dosed a human. In 2026 a new fundraise pinned a number to the ambition: $1.8 billion.

Medicine treats the diseases of aging one at a time. Retro thinks that's the wrong list.

Cancer, Alzheimer's, heart failure, frailty - modern medicine has a department for each. Retro's founding observation is uncomfortably simple: most of these are downstream of the same upstream process. Cells accumulate damage. Their repair and recycling systems slow down. Tissues lose the younger, fitter cells that kept them running. Call it aging, and roughly 90% of US healthcare spending traces back to it.

So the company refuses to chase symptoms. Instead it targets the cellular drivers of aging itself - on the theory that if you fix the engine, you stop replacing the parts one breakdown at a time. It is a tidy argument. It is also, conveniently, the hardest problem in biology.

A man who once built the world's smallest computer decided the next thing worth shrinking was the gap between lab and clinic.

Retro Biosciences was co-founded in 2018 by Joe Betts-LaCroix, Sheng Ding, and Matt Buckley, and launched publicly in 2021. Betts-LaCroix, the CEO, is better known in tech circles for helping invent one of the world's smallest personal computers - hardware that helped pave the way for tablets and laptops. He had been knocking around biomedicine since at least 2010. The bet he and his co-founders made was less about a single molecule than about speed: that a vertically integrated, in-house research engine could discover and develop a drug faster than the industry believed possible. The stated timeline - ship a drug "in the 2020s" - is the kind of thing biotech veterans politely call optimistic.

Three bets on aging, run at the same time, because the company can't afford to wait and see which one works.

Most startups pick a lane. Retro built three. The logic is portfolio-style: aging has multiple cellular drivers, so attack several in parallel and let the clinic sort out the winners.

The skeptic's question is fair: where are the numbers?

Longevity biotech is allergic to hard data, which is exactly why Retro's milestones matter. A first-in-human trial is not a cure. But it is the difference between a pitch deck and a regulated medicine. Here is the case so far, in figures.

Ten years. Healthy ones. That is the whole pitch, and it refuses to get smaller.

Retro calls itself a "generational pharma" - a company built to outlast the usual venture clock. The mission has not been softened into something safer: not "promote wellness," not "support healthy aging." The number is ten, the years must be healthy, and the target is the biology of aging itself. Everything else - the platforms, the trial, the billion-dollar rounds - is logistics in service of that sentence.

Who's in the arena. Retro is not alone. Altos Labs, Calico, NewLimit, Unity Biotechnology, BioAge, and Turn Biotechnologies are all circling the same question. The difference Retro presses is sequencing: it got a drug into a human first, and treats that as the whole point.

Back to Adelaide.

The volunteer who swallowed RTR242 will not live to 200 because of it. That is not the experiment. The experiment is narrower and far more consequential: can a drug measurably restore a single, failing cellular system - and can that restoration translate into a healthier brain? If the August data holds, Retro will have done the one thing the longevity field has mostly avoided. It will have shown its work.

And if it doesn't hold, the company has two more bets running and a balance sheet built to absorb the answer. That is the quiet design behind the loud mission. The pill in Adelaide is small. The question it is asking - whether aging is a treatable condition rather than an inevitable one - is the largest one a company can pick up. Retro Biosciences picked it up, wrote the goal on the homepage, and started dosing.